Abordaje integral y actualización terapéutica de la psoriasis pediátrica: perspectiva para el contexto latinoamericano. Tercera parte: actualización terapéutica
DOI:
https://doi.org/10.29176/30284163.2170Palabras clave:
Algoritmos terapéuticos, Fototerapia, Metotrexato, Psoriasis pediátrica, Terapia tópica, Tratamiento biológicoResumen
Objetivo: presentar una actualización terapéutica integral de la psoriasis pediátrica basada en evidencia científica actual, con enfoque en el contexto latinoamericano. Métodos: revisión narrativa de la literatura científica mediante búsqueda sistemática en bases de datos PubMed/Medline, Embase, LILACS, SciELO y Biblioteca Cochrane, período 2015-2025, utilizando términos MeSH y DeCS específicos para psoriasis pediátrica y tratamientos. Resultados: el manejo terapéutico actual ha evolucionado hacia intervenciones proactivas que incorporan precozmente terapias dirigidas. Los tratamientos tópicos (corticosteroides de baja-media potencia, análogos de la vitamina D e inhibidores de la calcineurina) controlan hasta el 40% de los casos leves. Para formas moderadas-graves, la fototerapia UVB de banda estrecha (311-313nm) y los tratamientos sistémicos convencionales (metotrexato en 0,2-0,7 mg/kg/semana y ciclosporina en 2,5-5 mg/kg/día) constituyen alternativas efectivas. Las terapias biológicas aprobadas incluyen inhibidores del FNT-α (etanercept, ≥2 años, adalimumab, ≥4 años), anti-IL-12/23 (ustekinumab, ≥6 años) y anti-IL17 (secukinumab/ixekizumab, ≥6 años), con dosificación pediátrica específica y excelente perfil de seguridad. Conclusiones: el paradigma terapéutico actual permite aspirar al control completo de la enfermedad mediante algoritmos individualizados que consideran gravedad, comorbilidades y características del paciente, adaptados al contexto sanitario latinoamericano.
Biografía del autor/a
Mayra Alejandra Sánchez Charria, Universidad Libre de Colombia
Residente de Dermatología, Universidad Libre, Cali, Colombia. Grupo de Investigación en Dermatología - GRINDERMA.
Juan Pablo Posso-García, Universidad Libre de Colombia
Residente de Dermatología, Universidad Libre. Cali, Colombia. Grupo de Investigación en Dermatología - GRINDERMA.
Guillermo González-Rodríguez, Universidad Libre de Colombia
Dermatólogo. Docente de Dermatología, Universidad Libre, Cali, Colombia.
Referencias bibliográficas
1. Luna PC, Abad ME, Larralde M, Boggio P, Ferrari B, Maccario MF, et al. Recomendaciones para el tratamiento de la psoriasis en Pediatría. Rev Fac Cien Med Univ Nac Cordoba. 2023;80(4):523-537. https://doi.org/10.31053/1853.0605.v80.n4.42874
2. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. https://doi.org/10.1016/j.jaad.2019.08.049
3. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94. https://doi.org/10.1016/S0140-6736(14)61909-7
4. Bronckers IMGJ, Paller AS, van Geel MJ, van de Kerkhof PCM, Seyger MMB. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-84. https://doi.org/10.1007/s40272-015-0137-1
5. Hebert AA, Browning J, Kwong PC, Duarte AM, Price HN, Siegfried E. Managing pediatric psoriasis: update on treatments and challenges—a review. J Dermatolog Treat. 2022;33(5):2433-42. https://doi.org/10.1080/09546634.2022.2059051
6. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-9. https://doi.org/10.1111/j.1365-2133.1995.tb16953.x
7. Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26(5):546-53. https://doi.org/10.1016/j.clindermatol.2007.10.023
8. Kortuem KR, Davis MD, Witman PM, McEvoy MT, Farmer SA. Results of Goeckerman treatment for psoriasis in children: A 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518-24. https://doi.org/10.1111/j.1525-1470.2010.01124.x
9. Vicente A, Pérez-Ferriols A, Batalla A, García-Fernandez L, Pérez B, Eiris N, et al. Documento de consenso del Grupo Español de Psoriasis (GPS) y del grupo Español de Dermatología Pediátrica (GEDP) de la Academia Española de Dermatología y Venereología (AEDV) sobre el manejo de la psoriasis pediátrica. Actas Dermosifiliogr. 2025;116(3):254-80. https://doi.org/10.1016/j.ad.2024.06.007
10. Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017;176(10):1339-54. https://doi.org/10.1007/s00431-017-2985-x
11. van Geel MJ, Mul K, Oostveen AM, van de Kerkhof PC, de Jong EM, Seyger MM. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363-9. https://doi.org/10.1111/bjd.12895
12. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76-80. https://doi.org/10.1111/j.1525-1470.2007.00341.x
13. Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059-67. https://doi.org/10.1016/j.jaad.2020.10.085
14. Lara-Corrales I, Ramnarine S, Lansang P. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25-33. https://doi.org/10.4137/CMPed.S8045
15. Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol Allied Sci. 1996;21(6):546-7. https://doi.org/10.1111/j.1365-2273
16. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989-1004. https://doi.org/10.1111/j.1468-3083.2010.03705.x
17. van Geel MJ, Oostveen AM, Hoppenreijs EP, Hendriks JC, de Jong EM, Seyger MM. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatolog Treat. 2015;26(5):406-12. https://doi.org/10.3109/09546634.2014.996515
18. Bronckers IMGJ, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384-92. https://doi.org/10.1001/jamadermatol.2019.4835
19. Mahe E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001 Nov;137(11):1532-3.
20. Lacour M, Mehta-Nikhar B, Atherton DJ, Harper JI. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol. 1996;134(6):1023-9. https://doi.org/10.1046/j.1365-2133.1996.d01-895.x
21. Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42-8. https://doi.org/10.1111/pde.14870
22. Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762-8. https://doi.org/10.1016/j.jaad.2010.04.004
23. Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40-9. https://doi.org/10.1016/S0140-6736(17)31189-3
24. Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603. https://doi.org/10.1016/j.jaad.2015.07.002
25. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938-47. https://doi.org/10.1111/jdv.17002
26. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821-38. https://doi.org/10.1007/s40257-018-0383-4
27. Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142-52. https://doi.org/10.1056/NEJMoa2102383
28. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgő Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-98. https://doi.org/10.1111/jdv.16915
29. Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628-37. https://doi.org/10.1111/bjd.19039
30. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-72. https://doi.org/10.1016/j.jaad.2018.11.057
31. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706-14.
32. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. https://doi.org/10.1111/bjd.16102
33. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841-50. https://doi.org/10.1016/j.jaad.2016.01.013
34. Gyldenløve M, Meteran H, Sørensen JA, Fage S, Egeberg A, Thyssen JP, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO). Lancet Reg Health Eur. 2023;30:100639. https://doi.org/10.1016/j.lanepe.2023.100639
Cómo citar
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Mayra Alejandra Sánchez Charria, Juan Pablo Posso-García, Guillermo González-Rodríguez

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.



